Following its extensive restructuring in the agricultural sector, Bayer is now concentrating its efforts entirely on its pharmaceutical division. However, as management outlines ambitious profitability targets for 2030, a new trade policy threat is emerging in its most crucial market. Potential U.S. tariffs pose a significant risk to the projected earnings from the company’s new flagship medications.
The Pivotal Role of the U.S. Market
The importance of the American market to Bayer’s strategic shift is underscored by a recent executive appointment. Nelson Ambrogio will assume leadership of Bayer U.S. Pharmaceuticals on May 1. Yet, reports of impending U.S. tariffs on goods from European production sites are causing concern across the industry. Given that the United States is the primary sales region for high-margin pharmaceuticals, market observers view these trade policy developments as a serious risk to the Leverkusen-based company’s growth plans.
Profitability Goals Driven by New Drugs
To counterbalance substantial cash outflows from other business units, the Pharmaceuticals division is being positioned as the central driver of future earnings. The company is forecasting mid-single-digit percentage sales growth from 2027 onward. By the end of the decade, Bayer aims to push its operating margin toward 30%.
Should investors sell immediately? Or is it worth buying Bayer?
This ambition rests on promising therapies such as the cancer drug Nubeqa, which is projected to generate approximately €2.4 billion in revenue next year. Management anticipates additional growth from Kerendia, as well as from pipeline candidates including Beyonttra, Lynkuet, and Asundexian.
Stock Performance and Strategic Hurdles
Bayer’s shares traded at €39.55 ahead of the weekend, currently moving through a period of consolidation after the volatility of recent years. The company’s future valuation is now largely dependent on whether its new medications can genuinely elevate margins to the targeted level. An escalation in U.S. trade policy would significantly complicate the achievement of these ambitious profitability goals.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from April 6 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 6.
Bayer: Buy or sell? Read more here...
